Some genes related with endometrial carcinoma prognosis have become a hopeful target for therapies in endometrial carcinoma, these targeting genes include mTOR inhibitors, EGFR tyrosine kinase inhibitors (erlotinib), and monoclonal antibodies to Her-2/neu (trastuzumab) [135–138]. This evidence concerns the gene MTOR and endometrial carcinoma.